VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith.
I am excited to extend a warm welcome to Nancy, Don, and Devyn as they join Aspects Board of Directors, said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. Each of them brings substantial experience in regenerative medicine and we are thrilled to have them join our mission as we move towards the next stage of growth.
About Aspects New Board Members
Dr. Nancy Krieger is the Chief Medical Officer of Talaris Therapeutics, a recently public late-clinical stage cell therapy biotech. She has over 18 years of global experience in the biopharmaceutical industry, including leadership positions at Bristol Myers Squibb and Novartis in areas spanning solid organ and stem cell transplantation, immunology, rare disorders, and chronic kidney and liver diseases. Before joining industry, Dr. Krieger had an active practice in liver transplantation as well as a basic science laboratory. She completed her transplant fellowship at the University of Wisconsin and general surgical residency at Stanford University, including a postdoctoral fellowship in Stanfords immunology department. Dr. Krieger earned her MD at Columbia University College of Physicians and Surgeons.
I am thrilled to be joining the Board of Aspect Biosystems, said Dr. Nancy Krieger. As a transplant surgeon I am passionate about the tremendous potential of Aspects 3D bioprinting technology for regenerative cellular therapies, with the ultimate possibility of replacing organ transplants without the need for life-long immunosuppression.
Dr. Don Haut is currently the CEO of Carmine Therapeutics, a discovery-stage, non-viral gene therapy company with operations in Boston and Singapore. Throughout his career, Dr. Haut has completed transactions exceeding $8 billion. As Chief Business Officer of AskBio, he led the firms business development activities and spearheaded AskBios $4 billion acquisition by Bayer AG. Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, The Medicines Company, Promedior, Histogenics, Sherlock Bio, and AskBio. He earned his PhD in Molecular Biology from the Medical School at the University of Missouri-Columbia, and an MBA from Washington Universitys Olin School of Business.
When I first learned about what Aspect Biosystems was doing, my first thought was Wow! said Dr. Don Haut. My second thought was it would be great to work with those folks they are really onto something. So, I am delighted to be joining Aspect the team, the technology, and the mission are all outstanding."
Dr. Devyn Smith joined Arbor Biotechnologies as CEO in 2021 after concluding his role as COO of Sigilon Therapeutics. Prior to Sigilon, Dr. Smith worked in a variety of roles at Pfizer Inc., including COO of the UK-based Neusentis Unit focused on discovering and developing cell therapies. He received his PhD in Genetics from Harvard Medical School. He is an inventor on multiple patents and has published in leading scientific journals throughout his career. Dr. Smith is a board member and officer for the Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.
I am excited to join the board of Aspect Biosystems, said Dr. Devyn Smith. I look forward to partnering with Tamer and the talented team at Aspect to build a successful company that delivers novel cellular therapies to patients with high unmet needs.
For full list of board members, visit http://www.aspectbiosystems.com/about.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company creating bioprinted tissue therapeutics to transform how we treat disease. Aspect is combining its proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create a pipeline of allogeneic tissues that replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at aspectbiosystems.com.
Original post:
Aspect Biosystems Appoints Three New Board Members - Business Wire
- Soils, Plant Nutrition and Nutrient Management | MU Extension - October 13th, 2022
- Missouri S&T welcomes new faculty - Missouri S&T News and Research - October 4th, 2022
- Questioning the wisdom of the late Susan Solomon Catholic World Report - Catholic World Report - September 25th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 ... - September 16th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the... - September 16th, 2022
- Sunflower: The story of this summer goddess begins with search for love Pratt Tribune - Pratt Tribune - September 16th, 2022
- Is the ISS an Ideal Place to Grow Billions of Stem Cells? Scientists Seem to Think So - iTech Post - July 19th, 2022
- UM-Dearborn graduate hopes to make it to space - Dearborn Press and Guide - July 19th, 2022
- Preventing and Managing Plant Diseases | MU Extension - June 4th, 2022
- Plants and Their Environment | MU Extension - June 4th, 2022
- Can you mix COVID vaccines? What that could mean for Moderna and J&J boosters - CNET - October 16th, 2021
- Missouri S&T hosts first in series of national critical minerals workshops - Missouri S&T News and Research - July 21st, 2021
- The race for a steak grown in the laboratory - Techno EA - January 12th, 2020
- Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times - November 30th, 2019
- The Ihrie Lab @ Vanderbilt | Neural stem cells, neural ... - May 23rd, 2019
- Saint Louis, Missouri - Stem Cells Transplant Institute - January 23rd, 2019
- Missouri University of Science and Technology - Wikipedia - December 10th, 2018
- Bluetail Medical Group Regenerative Medicine Experts - July 8th, 2018
- Brain's Stem Cells Slow Aging in Mice - Scientific American - July 30th, 2017
- Brain's stem cells slow ageing in mice - Nature.com - July 30th, 2017
- Chemical persuasion by David Sparks Ph.d, click here for bio - AgInfo.net (press release) (registration) (blog) - July 30th, 2017
- Pig research could improve IVF in humans - Wallace's Farmer - July 30th, 2017
- Neuralstem, Inc. (CUR) Just Recorded A Sigfniciant Increase - Weekly Register - July 9th, 2017
- stem cells - decodingscience.missouri.edu - December 1st, 2016
- Stem cells can repair torn tendons or ligaments ... - October 6th, 2016
- Stem Cells for Orthopedics Missouri & Florida - September 18th, 2016
- Stem Cells Quotes - Notable Quotes - September 18th, 2016
- Stem Cells | Topics | Christianity Today - September 13th, 2016
- Stem Cell Therapy In Springfield, Missouri - Cherry Health ... - August 8th, 2016
- Human brainwaves light up mouse genes - November 11th, 2014
- Missouri Constitutional Amendment 2 (2006) - Wikipedia ... - October 27th, 2014
- PRP Therapy, Adult Stem Cell Therapy, Regenerative ... - August 29th, 2014
- MU News Bureau | MU News Bureau - University of Missouri - August 29th, 2014
- Missouri Stem Cell Treatments | Stem Cell Treatments - August 22nd, 2014
- The Missouri Embryonic Stem Cell Research Initiative - August 22nd, 2014
- Laws Governing Stem Cell Research - Missouri Right to Life - August 22nd, 2014
- Catholic school officials partake in ALS challenge despite warning - August 22nd, 2014